A year after a major layoff round at its Allergan headquarters in California, AbbVie is making more edits to its workforce with a new round of 85 layoffs.  | The layoffs at AbbVie's Irvine, California ...

The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...

The CHMP has put its stamp of approval on Boehringer Ingelheim’s Jascayd for two lung disorders—idiopathic pulmonary fibrosis ...

AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California, while Novartis is cutting more staff at ...

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | ...

A web of mail-order pharmacies, wholesalers and patient services groups connected to the self-styled largest Pentecostal ...

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for its top-selling ...

Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...

Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...